Form D · Pharmaceuticals
HOOKIPA Pharma Inc.
New York, NY · CIK 0001760542
Offering snapshot reported Feb 27, 2019 · SEC filing
- Reported sold
- $37.4M Indefinite offering
- Investors reported
- 9 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 15, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 27, 2019 | Initial | $37,432,050 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-333647
Source: Form D, filed Feb 27, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Joern Aldag | Director, Executive |
| Reinhard Kandera | Director, Executive |
| Michael Kelly | Director |
| Paul Henri Lambert | Director |
| Christoph Lengauer | Director |
| Julie O'neill | Director |
| Graziano Seghezzi | Director |
| Sander Van Deventer | Director |
| Jan Van De Winkel | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
430 East 29 Th Street 14 Th Floor
New York, NY, 10016
New York, NY, 10016